Aurobindo pharma share price

If you click ' Accept all', we and • display personalised ads and content based on interest profiles • measure the effectiveness of personalised ads and content, and • develop and improve our products and services If you do not want us and our partners to use cookies and personal data for these additional purposes, click ' Reject all'. If you would like to customise your choices, click ' Manage privacy settings'. You can change your choices at any time by clicking on the 'Privacy & cookie settings' or 'Privacy dashboard' links on our sites and apps. Find out more about how we use your personal data in our

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. Importantly, Aurobindo Pharma Limited ( When Is Debt A Problem? Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together. What Is Aurobindo Pharma's Debt? You can click the graphic below for the historical numbers, but it shows that as of March 2023 Aurobindo Pharma had ₹48.6b of debt, an increase on ₹23.7b, over one year. However, it does have ₹62.4b in cash offsetting this, leading to net cash of ₹13.7b. NSEI:AUROPHARMA Debt to Equity History June 14th 2023 A Look At Aurobindo Pharma's Liabilities Zoomi...

Aurobindo Pharma has laid an emphasis on R&D operations and in its quarterly earnings for January-March 2023, the company reported that its R&D spending stood at Rs 410.7 crore, 6.3 per cent of revenues. This quarter, Aurobindo Pharma received final approval for 26 abbreviated new drug applications (ANDAs), including four injectable products.

Aurobindo Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Aurobindo Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/41180/aurobindo-pharma-ltd/ Get Aurobindo Pharma Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine f...

Technicals On the technical charts, the 200-Day Moving Average (DMA) of the stock stood at Rs 506.01 on May 16, while the 50-DMA was at Rs 538.63. If a stock trades above 50-DMA and 200-DMA, it usually means the immediate trend is upward. On the other hand, if the stock trades well below 50-DMA and 200-DMA both, it is considered as bearish trend and if trades between these averages, then it suggests the stock can go either way. Don’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp. • 862.50 04:02 PM | 14 Jun 2023 42.60 (5.20%) 1,779.35 04:02 PM | 14 Jun 2023 41.40 (2.38%) 113.80 04:02 PM | 14 Jun 2023 2.65 (2.38%) 772.85 04:02 PM | 14 Jun 2023 16.20 (2.14%) • 7,096.85 04:02 PM | 14 Jun 2023 -69.90 (-0.98%) 1,323.25 03:59 PM | 14 Jun 2023 -13.00 (-0.97%) 977.70 04:02 PM | 14 Jun 2023 -8.15 (-0.83%) 827.95 04:02 PM | 14 Jun 2023 -6.40 (-0.77%)

Sector Healthcare Compare with Sector peers Industry Pharmaceuticals & Drugs Compare with Industry peers Website http://www.aurobindo.com Market Cap 40,130.94 Cr. Enterprise Value(EV) 38,908.26 Cr. 2023-03 Financial Indicators • Consolidated • Standalone Earnings per share (EPS) 32.90 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) 20.82 Trailing Twelve Months Ending 2023-03 Industry PE 34.47 Trailing Twelve Months Ending 2023-03 Book Value / Share 458.07 Trailing Twelve Months Ending 2023-03 Price to Book Value 1.50 Calculated using Price: 684.90 Dividend Yield 1.31 Period Ending 2022-03 No. of Shares Subscribed 58.59 Cr. 585,938,609 Shares FaceValue 1 About Aurobindo Pharma Ltd. Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. ...

Consolidated revenue from operations stood at ₹6,473 crore in Q4FY23, registering a growth of 11.4 per cent from ₹5,809.4 crore in Q4 of the previous fiscal. EBITDA before R&D stood at ₹1,412.9 crore in Q4FY23, rising by 0.5 per cent YoY and 3.2 per cent QoQ respectively. EBITDA margins came in at 15.5 per cent in Q4FY23, contracting as against 16.8 per cent in Q4FY22 but were up from a margin of 14.9 per cent in Q3FY23. The stock fell 0.68 per cent in the next trading session on May 28. ₹506 crore, revenue up over 11% Most brokerage firms found the March quarter numbers of the company in line with expectations. Most of them retained their earlier views while some of them raised the target price. Brokerage firm Prabhudas Lilladher has a buy call on the stock and raised the target price to ₹660 from ₹565 earlier. The brokerage firm believes "Our FY24E and FY25E EPS (earnings per share) estimates stand increased by 6 per cent and 4 per cent, respectively, to factor in higher margins. Aurobindo Pharma’s Q4FY23 EBITDA of ₹1,000 crore (up 5 per cent QoQ) with an operating profit margin of 15.5 per cent (up 60 bps QoQ) was in-line with our estimate," said Prabhudas Lilladher. The brokerage firm expects the margin trajectory to improve from FY24 as it believes pick-up in US sales hinges on timely niche approvals and stabilisation of pricing pressure in the base business. Kotak Institutional Equities maintained an 'add' call on the stock but raised the target price to ₹625 from ₹5...

The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income. These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance. Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing. Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-a...

Synopsis The S&P BSE Sensex and Nifty50 are expected to consolidate following positive global cues, as India VIX rises by 2.15% from 11.12 to 11.38. Maximum call OI is at 18600 with maximum put OI at 18500, causing a broader trading range between 18300 and 18800 and an immediate range between 18450 and 18700 zones. Nifty is holding above 18580 zones for an up move towards 18666 and 18750 zones, with downside support at 18480 and 18442 zones. Stocks such as HPCL, RCF and Jindal Steel are recommended for trading with a short-term horizon. On the options front, the weekly maximum Call OI is placed at 18600 and then towards 18800 strikes while the maximum Put OI is placed at 18500 and then towards 18600 strikes. Call writing is seen at 18750 then 18800 strikes while Put writing is seen at 18550 then 18400 strikes. “Options data suggests a broader trading range in between 18300 to 18800 zones while an immediate trading range in between 18450 to 18700 zones,” Chandan We have collated stocks from various experts for traders who have a short-term trading horizon: Expert: Jatin Gedia, Technical Research Analyst, Sharekhan by BNP Paribas told ETBureau RCF: Buy| Target Rs 124| Stop Loss Rs 103 Expert: Kunal Bothra, Market Expert told ETNow PolicyBazaar: Buy| Target Rs 666| Stop Loss Rs 588 Expert: Nooresh Merani, an independent technical analyst told ETNow (Disclaimer: Recommendations, suggestions, views and opinions given by experts are their own. These do not represent the views of...